Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
出版年份 2020 全文链接
标题
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-10-24
DOI
10.1186/s12933-020-01154-w
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial
- (2020) Ameur M. Manceur et al. CURRENT MEDICAL RESEARCH AND OPINION
- Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study
- (2020) Digsu N. Koye et al. DRUGS
- Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
- (2020) Jakob S. Knudsen et al. PLoS One
- Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study
- (2020) Björn Pasternak et al. DIABETES CARE
- Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
- (2020) David Z. I. Cherney et al. DIABETOLOGIA
- UTILIZATION OF GLUCOSE-LOWERING DRUGS IN PATIENTS WITH T2DM AND ESTABLISHED CVD IN US: A DESCRIPTIVE STUDY USING OPTUM CLINFORMATICS DATA
- (2020) Michael Ganz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
- (2020) Björn Pasternak et al. BMJ-British Medical Journal
- The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
- (2020) Win L. Yin et al. Diabetes Therapy
- Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
- (2020) Marco Castellana et al. Cardiovascular Diabetology
- 29-LB: Physicians’ Chronic Kidney Disease (CKD) Awareness over Time in Type 2 Diabetes (T2D)
- (2020) JOHN SCHEMPF et al. DIABETES
- 624-P: Primary Care Education Leads to Improved Diabetes Knowledge and Clinical Practice
- (2020) RYAN WOOLLEY et al. DIABETES
- Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
- (2020) Thomas M. Caparrotta et al. DIABETES CARE
- Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology
- (2020) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
- (2020) Shintaro Sakurai et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice
- (2020) Annemarie B. van der Aart-van der Beek et al. Nature Reviews Nephrology
- Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
- (2020) Chintan N. Koyani et al. PHARMACOLOGICAL RESEARCH
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
- (2020) Shun Kohsaka et al. Lancet Diabetes & Endocrinology
- Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
- (2020) Enrico Longato et al. BMJ Open Diabetes Research & Care
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis
- (2019) Rod S Taylor et al. European Journal of Preventive Cardiology
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
- (2019) Agnes Bosch et al. Cardiovascular Diabetology
- A Big Win for Diabetic Kidney Disease: CREDENCE
- (2019) David Z.I. Cherney et al. Cell Metabolism
- Effect of Health Information Technologies on Cardiovascular Risk Factors among Patients with Diabetes
- (2019) Yilin Yoshida et al. Current Diabetes Reports
- CARMELINA®: an important piece of the DPP-4 inhibitor CVOT puzzle
- (2019) Guntram Schernthaner et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1477-P: Insights from Type 2 Diabetes Patients Suggest Need for Cardiovascular Health Education
- (2019) KEATON C. STONER et al. DIABETES
- 1247-P: Anticipating the Impact of 2019 Guidelines: Use of SGLT2i and GLP-1RA in Patients with Diabetes and Cardiovascular Disease
- (2019) CORI R. RATTELMAN et al. DIABETES
- 1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
- (2019) AJINKYA PAWAR et al. DIABETES
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lifetime benefits of early detection and treatment of diabetic kidney disease
- (2019) Julia Thornton Snider et al. PLoS One
- PDB126 COMPARATIVE HEALTHCARE COSTS AND MEDICATION BURDEN IN REAL-WORLD PATIENTS AUGMENTING METFORMIN MONOTHERAPY WITH EMPAGLIFLOZIN FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
- (2019) A. Pawar et al. VALUE IN HEALTH
- PDB128 REDUCED HEALTHCARE UTILIZATION IN PATIENTS USING EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
- (2019) M. Najafzadeh et al. VALUE IN HEALTH
- SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
- (2019) Guntram Schernthaner et al. BMC Endocrine Disorders
- Trends in Antidiabetic Utilization and Expenditure in Denmark: A 22‐Year Nationwide Study
- (2019) Camilla Bang et al. DIABETES OBESITY & METABOLISM
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
- (2019) Pedro Monteiro et al. AGE AND AGEING
- Active participation of patients with type 2 diabetes in consultations with their primary care practice nurses – what helps and what hinders: a qualitative study
- (2019) E. du Pon et al. BMC HEALTH SERVICES RESEARCH
- P5003Reduced healthcare utilization in routine care initiators of empagliflozin with and without heart failure: interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
- (2019) A Pawar et al. EUROPEAN HEART JOURNAL
- Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus
- (2019) David Z.I. Cherney et al. AMERICAN JOURNAL OF NEPHROLOGY
- Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
- (2019) Alana Aragón-Herrera et al. BIOCHEMICAL PHARMACOLOGY
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
- (2019) Anders Jorsal et al. EUROPEAN HEART JOURNAL
- Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents
- (2019) Yen-Wen Chen et al. JOURNAL OF MEDICAL ECONOMICS
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)
- (2018) Suzanne V. Arnold et al. AMERICAN HEART JOURNAL
- Cost-of-illness studies in heart failure: a systematic review 2004–2016
- (2018) Wladimir Lesyuk et al. BMC Cardiovascular Disorders
- Are We Ready to Bell The Cat?
- (2018) Michael E. Nassif et al. CIRCULATION
- Weight Management in Patients with Type 2 Diabetes: a Multidisciplinary Real-world Approach
- (2018) Osama Hamdy et al. Current Diabetes Reports
- Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities
- (2018) SUZANNE V. ARNOLD et al. DIABETES
- Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- (2018) M. ANGELYN BETHEL et al. DIABETES
- Clinical Inertia in Type 2 Diabetes Management: Evidence From a Large, Real-World Data Set
- (2018) Kevin M. Pantalone et al. DIABETES CARE
- Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany
- (2018) Katharina Kähm et al. DIABETES CARE
- Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry
- (2018) Suzanne V. Arnold et al. DIABETES OBESITY & METABOLISM
- Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
- (2018) Guntram Schernthaner et al. DIABETOLOGIA
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical inertia versus overtreatment in glycaemic management
- (2018) Kamlesh Khunti et al. Lancet Diabetes & Endocrinology
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease
- (2018) Naim Shehadeh et al. Cardiovascular Diabetology
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide-1 receptor action in the vasculature
- (2018) Malak Almutairi et al. PEPTIDES
- Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
- (2018) Jennifer Okemah et al. ADVANCES IN THERAPY
- Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial
- (2018) Irene Hramiak et al. Canadian Journal of Diabetes
- Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
- (2018) Guntram Schernthaner et al. Cardiovascular Diabetology
- GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
- (2018) Andrei C. Sposito et al. Cardiovascular Diabetology
- Changing the care pathway for Type 2 diabetes at the time of diagnosis: the role of the multidisciplinary team
- (2018) M. B. Whyte et al. DIABETIC MEDICINE
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Type 2 diabetes in patients with end-stage kidney disease: influence on cardiovascular disease-related mortality risk
- (2018) Wai H Lim et al. MEDICAL JOURNAL OF AUSTRALIA
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes
- (2018) D. Giugliano et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature
- (2017) Kelly R. Burke et al. PHARMACOTHERAPY
- Knowledge of risk factors for diabetes or cardiovascular disease (CVD) is poor among individuals with risk factors for CVD
- (2017) Monique F. Kilkenny et al. PLoS One
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
- (2017) Suzanne V Arnold et al. European Journal of Preventive Cardiology
- Clinical inertia—Time to reappraise the terminology?
- (2017) Kamlesh Khunti et al. Primary Care Diabetes
- Clinical inertia to insulin initiation and intensification in the UK: A focused literature review
- (2017) Kamlesh Khunti et al. Primary Care Diabetes
- The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-Centered Multidisciplinary Diabetes Program (the NADIR Study)
- (2016) Harpreet S. Bajaj et al. Canadian Journal of Diabetes
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- A systematic review of interventions targeting primary care or community based professionals on cardio-metabolic risk factor control in people with diabetes
- (2016) S. Seidu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING
- (2016) Jay Lin et al. Endocrine Practice
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Communication and patient participation influencing patient recall of treatment discussions
- (2016) Claude Richard et al. HEALTH EXPECTATIONS
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Empagliflozin (Jardiance) to the NHS: Estimation of Budget and Event Impact Based on Empa-Reg Outcome Data
- (2016) I Daacke et al. VALUE IN HEALTH
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease
- (2015) Allan J. Collins et al. Kidney International Supplements
- Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease)
- (2014) Lynda A. Szczech et al. PLoS One
- Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
- (2014) William David Strain et al. Diabetes Therapy
- Barriers and Potential Solutions to Providing Optimal Guideline-Driven Care to Patients With Diabetes in the U.S.
- (2013) R. A. Vigersky et al. DIABETES CARE
- Computerized Decision Support Systems in Primary Care for Type 2 Diabetes Patients Only Improve Patients' Outcomes when Combined with Feedback on Performance and Case Management: A Systematic Review
- (2013) Frits G.W. Cleveringa et al. Diabetes Technology & Therapeutics
- Non-adherence to diabetes guidelines in primary care – The enemy of evidence-based practice
- (2012) Samuel Seidu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Estimating the financial cost of chronic kidney disease to the NHS in England
- (2012) Marion Kerr et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program
- (2011) Adam Whaley-Connell et al. CardioRenal Medicine
- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
- (2010) G. Schernthaner et al. DIABETOLOGIA
- Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2010) P. L. Drury et al. DIABETOLOGIA
- Diabetes Mellitus and CKD Awareness: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES)
- (2009) Adam Whaley-Connell et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started